Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director,...
-
Upload
samantha-daniels -
Category
Documents
-
view
213 -
download
0
Transcript of Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director,...
![Page 1: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/1.jpg)
Clinical and Translational Research:Expectations and Goals
Daniel E. Ford, M.D., M.P.H.Director, Institute for Clinical and Translational ResearchVice Dean for Clinical Investigation
![Page 2: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/2.jpg)
Clinical Research at Johns Hopkins
• Comprehensive in Scope• Cancer Center• Research in children• Neurosciences• Drug abuse
• Investigator Initiated• Large Discovery Pipeline• Expertise in Moving Discoveries to Population • Fortunate to Have Large Number of Trainees
Interested in Research
![Page 3: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/3.jpg)
Research at ClOffJohns Hopkins Medicine
By Calendar Year Last updated 4/5/2010
New Applications 2007 2008 2009
NHSR 35 48 99
New Exempt 443 364 311
New Expedited 561 688 830
New Convened 418 520 569
Total New 1457 1620 1809
Applications 2007 2008 2009
Active eIRB Applications 1552 2198 2890
Active Paper Applications 1051 859 554
Active SOM IRB 2603 3057 3444
WIRB Active Applications 405 297 200
CIRB Active Applications 32 58 63
Total Active 3040 3412 3707
Randomized Clinical Trials 2007 2008 2009
Active Randomized Clinical Trials 724 815 854
New Randomized Clinical Trials 247 376 405
![Page 4: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/4.jpg)
Commercial Applications 2007 2008200
9
Active Commercial 550 543 487
New Commercial 262 322 270
Commercial Clinical Trials 2007 2008
2009
Active Commercial Clinical Trials 385 385 360
New Commercial Clinical Trials 181 202 243
Using Drugs/Devices 2007 2008200
9
Active Applications Using Drugs 869 1024 1091
New Applications Using Drugs 282 346 386
Active Applications using Devices 288 327 245
New Applications using Devices 104 118 102
IDE/INDs Applications 2007 2008200
9
Investigator/Sponsor Held Active Applications using INDs 383 496 523
New Applications using INDs 157 198 156
Active INV Held INDs 74 118 162
New INV Held INDs 13 55 82
Active Applications using IDEs 12 29 44
New Applications using IDEs 9 21 20
Active INV Held IDEs 7 13 14
New INV Held IDEs 3 3 2
![Page 5: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/5.jpg)
Sponsored Project SourcesJohns Hopkins SOM – Prorated Awards
0
100
200
300
400
500
600
700
Fiscal Years
$ (M
illi
on
s)
Commercial 32.8 40.6 39.7 43.9 49.8 50 53.6 69.4 62.9 52.6
Other 38.7 45.2 50.4 56.7 60.6 66.9 70.4 103 97.9 107
Federal 212 209 209 244 299 329 399 451 461 456
97 98 99 0 1 2 3 4 5 6
![Page 6: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/6.jpg)
Translational Medicine
• T1 – “the transfer of new understandings of disease mechanisms gained in the laboratory into the development of new methods for diagnosis, therapy, and prevention and their first testing in humans.”
• T2 – “the translation of results from clinical studies into everyday clinical practice and health decision making.”
• IOM Clinical Research Roundtable
![Page 7: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/7.jpg)
Translational Research Activities
• T1 activities included: 1) the translation of basic discovery into mechanistic studies in cell lines or animals, 2) the translation of mechanistic studies into initial human testing, and 3) the translation of initial human testing into proof of efficacy.
• The T2 activities included 1) the translation of proof of efficacy into proof of effectiveness in a usual care setting, and 2) research aimed at enhancing the adoption of best practices in the community
![Page 8: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/8.jpg)
Conclusions
• 69% responded they are translational researchers (9% other survey but different definition)
• PhD and fellows report less translational activity
• Barriers to translational research are as expected but substantial
![Page 9: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/9.jpg)
84
44
43
33
30
20
11
5
0 10 20 30 40 50 60 70 80 90
Translational research is not part of my research agenda or
is not central to the goals of my research program.
I don’t have the resources (funding, space, equipment,
technology) for making my research more translational.
I have not yet identified an appropriate translational
research question to pursue.
I am not sure what the next translational step would be for
my research.
I haven’t identified or secured the colleagues or
collaborators I need to make my work more translational.
I don’t have the guidance or mentorship I need to make my
research more translational.
I don’t have the training or expertise I need to make my work
more translational.
I have methodological obstacles to making my research
more translational.
It is premature for me to consider translational research.
Number of Respondents (n=205)
It is premature for me to consider translational research.I have methodological obstacles to making my research more translational.I don’t have the training or expertise I need to make my research more translational.I don’t have the guidance or mentorship I need to make my research more translational. I haven’t identified or secured the colleagues or collaborators I need to make my work more translational.I am not sure what the next translational step is
I have not yet identified an appropriate translational research question to pursue.
I don’t have the resources (funding, space, equipment, technology) for making my research more translational.Translational research is not part of my research agenda or is not central to the goals of my research program.
Barriers to Translational Research (n=205)
![Page 10: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/10.jpg)
Translational Pathway
Basic Discovery
MechanisticStudies
Initial Human Testing
Proof of Efficacy
Proof of Effectiveness
Diffusion toAll HealthCare Settings
21
![Page 11: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/11.jpg)
Institute for Clinical and Translational ResearchInfluence on Scientific Discovery
Ins
titu
te P
rog
ram
s
Enhancing Formulation of Creation of Development Conduct Analysis of PublicationObservation Scientific Question Research Team Study Protocol of Study Study Data Impact Study
Advisory Boards
Protocol Review
Translational Science Forums
Science Cores
Innovation Groups
Biostatistical Support
Regulatory Support
ATIP
Research Ethics
Clinical Research Units
Clinical Research Participant Core
Data/Safety Monitoring
Community Engagement Program
Biomedical Informatics
Navigator Program
Research Education and Training
![Page 12: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/12.jpg)
Impetus for the CTSA Program
Implementing biomedical discoveries Implementing biomedical discoveries made in the last 10 years demands an made in the last 10 years demands an evolution of clinical science.evolution of clinical science.
New prevention strategies and treatments New prevention strategies and treatments must be developed, tested, and brought must be developed, tested, and brought into medical practice more rapidly.into medical practice more rapidly.
CTSA awards will lower barriers between CTSA awards will lower barriers between disciplines, and encourage creative, disciplines, and encourage creative, innovative approaches to solve complex innovative approaches to solve complex medical problems.medical problems.
These clinical and translational science These clinical and translational science awards will catalyze change -- breaking awards will catalyze change -- breaking silos, breaking barriers, and breaking silos, breaking barriers, and breaking conventions.conventions.
![Page 13: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/13.jpg)
Johns Hopkins and Translational Medicine
• Need to support researchers at all career levels• Progress in translational medicine requires development of teams of
researchers that appreciate all phases • Clinical and translational researchers will continue to develop more
technical and specialized approaches. Handoffs require active coordination (project coordinators).
• Do to increasing regulations, researchers will need to rely more on systematized solutions at institutional or national level
• Academic organizations need to partner better with other organizations to increase efficiency (industry, payers, patient groups)
• Need to balance resources/support for early and late translation• Academic centers need better management structure to
systematically monitor research process and barriers
![Page 14: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/14.jpg)
MT
WY
ID
WA
OR
NV
UT
CA
AZ
ND
SD
NE
CO
NM
TX
OK
KS
AR
LA
MO
IA
MN
WI
IL IN
KY
TN
MS AL GA
FL
SC
VAWV
OH
MI
NY
PA
MD
DE
NJ CTRI
MA
ME
VT
NH
AK
HI
Building a National CTSA Consortium
Since 2006Since 2007
Participating Institutions
![Page 15: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/15.jpg)
CTSAWeb.org
![Page 16: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/16.jpg)
Consortium Governance & Organization
Governance Manual available at http://ctsaweb.org/Docs/CTSA_Governance_Manual.pdf
![Page 17: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/17.jpg)
Institute for Clinical and Translational Research
• Goals – Academic Home for Clinical and Translational
Researchers– Expand the Working Relationships of Clinical
Investigators with Basic Scientists and Population-oriented Scientists
– Coordinate Translational Research Activities to Increase Innovation and Speed of Translation
![Page 18: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/18.jpg)
Institute for Clinical and Translational Research
• Goals – Support Training of Clinical and Translational
Research Faculty and Staff– Provide Centralized Support for Research Where
Efficient– Measure and Track Efficiency of Human Subjects
Research to Address Barriers
• Director – Daniel Ford, MD, MPH Vice Dean for Clinical Investigation
![Page 19: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/19.jpg)
Deputy Directors of the Institute for Clinical and Translational Research
• Dr. Charles Balch• Dr. Stephen Desiderio• Dr. Charles Flexner• Dr. Elizabeth Jaffee• Dr. Pete Miller• Dr. Pamela Ouyang• Dr. Jeff Rothstein• Dr. Pamela Zeitlin
![Page 20: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/20.jpg)
Trial Design
Advanced Degree-Granting
Programs
Participant& CommunityInvolvement
RegulatorySupport
Biostatistics
ClinicalResources
BiomedicalInformatics
Research participantRecruitment office
Johns HopkinsJohns Hopkins ICTRICTR
NIH & other government
agencies
Healthcare organizations
IndustryIndustry
Johns Hopkins Institute for Clinical and Translational Research
![Page 21: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/21.jpg)
Johns Hopkins ICTR Progams
• Translational research training– K junior faculty/fellows– Medical students– Research staff and community physicians
• Clinical Research Units – 1200 inpatient research bed days– Over 10,000 outpatient research visits– Pediatric and adult beds including Bayview
![Page 22: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/22.jpg)
Johns Hopkins ICTR Progams
• Biostatistical Consultation
• Innovative Methodology Workgroups
• Clinical Research Ethics Consultations
• Data and Safety Monitoring Services
• Translational Research Navigators (project managers)
• Clinical Research Management Database
![Page 23: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/23.jpg)
Johns Hopkins ICTR Progams
• Basic Discovery Translational Forum• Clinical Sciences Translational Forum• Accelerated Translational Incubator
Program (ATIP) support pilots• Research Participant Recruitment and
Retention Program• Community Research Networks Office• Secondary Translation or Knowledge
Transfer Office
![Page 24: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/24.jpg)
Clinical Research Management System
BudgetingSponsor Billing
Investigators Research Nurse
Data Manager
Insurance Clearance
Budgeting by Dept. Admin.
ProgramManager
Patient/Protocol Registry
Pharmacy CoreFacilities
Labs SoMLeadership
Billing Compliance
IRB
EligibilityScreening
EPR/Labs Integration
IRB Integration
ProtocolSchema / Patient
Calendar
BillingCompliance
External Recruiting
Website
JHED/Site Minder Integration
Data Warehouse
Library Research
Forms
Work InProgress
CurrentlyIn Use
PossibleFuture
FunctionalityKey:
![Page 25: Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.](https://reader030.fdocuments.in/reader030/viewer/2022032606/56649eb65503460f94bbff29/html5/thumbnails/25.jpg)
Translational Cores
• Genetics Core
• Proteomics/Biomarker Core
• Drug and Vaccine Development Core